Want to see IN:WANBURY full AI Analyst Report?
Top Page
Wanbury Limited
(WANBURY)
Select Model
Select Model
Rating:49Neutral
Price Target:
₹198.00
▼(-40.45% Downside)
Action:Reiterated
Date:10/01/26
The score is constrained primarily by weak financial quality (poor cash generation and high leverage despite improved reported profitability) and bearish technical momentum (below major moving averages with negative MACD). A relatively modest P/E provides some valuation support but is not enough to offset the cash-flow and trend risks.
Positive Factors
Revenue Expansion
Continued revenue expansion indicates that Wanbury is maintaining demand across its pharmaceutical activities despite year-to-year variability. A larger revenue base can support operating scale, broaden the platform for formulations and APIs, and provide a foundation for sustained earnings improvement.
Negative Factors
Weak Cash Conversion
Minimal operating cash flow despite healthy reported income indicates that accounting profits are not converting reliably into cash. Deeply negative free cash flow can increase dependence on external funding and constrain the company’s ability to finance growth, investment, or obligations internally.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Expansion
Continued revenue expansion indicates that Wanbury is maintaining demand across its pharmaceutical activities despite year-to-year variability. A larger revenue base can support operating scale, broaden the platform for formulations and APIs, and provide a foundation for sustained earnings improvement.
Read all positive factors
Wanbury Limited (WANBURY) vs. iShares MSCI India ETF (INDA)
Market Cap
₹7.59B
Dividend Yield1.2%
Average Volume (3M)13.49K
Price to Earnings (P/E)11.5
Beta (1Y)1.78
Revenue Growth3.63%
EPS Growth24.22%
CountryIN
Employees1,200
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)17.29
Shares Outstanding34,966,927
10 Day Avg. Volume14,512
30 Day Avg. Volume13,495
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)4.96
Price to Sales (P/S)1.10
P/FCF Ratio-12.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)24.2
Revenue Forecast (FY)₹8.76B
Wanbury Limited Business Overview & Revenue Model
Company Description
Wanbury Limited is an Indian pharmaceutical company engaged in the development, manufacturing, and commercialization of both finished drug products (formulations) and active pharmaceutical ingredients (APIs). The company's diverse range of formula...
How the Company Makes Money
Wanbury Limited makes money by selling pharmaceutical products across two core business lines: (1) Finished-dosage formulations (medicines sold as tablets, capsules, etc.) and (2) Active pharmaceutical ingredients (APIs) supplied to other drug man...
Wanbury Limited Financial Statement Overview
Summary
Income Statement
66
Positive
Balance Sheet
50
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Jun 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.53B | 6.50B | 6.00B | 5.74B | 4.98B | 5.11B |
| Gross Profit | 2.65B | 2.40B | 3.05B | 2.65B | 1.89B | 2.04B |
| EBITDA | 955.38M | 1.04B | 798.13M | 985.49M | 234.91M | 1.13B |
| Net Income | 558.87M | 661.35M | 305.30M | 559.56M | -103.96M | 814.74M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 5.18B | 4.14B | 3.43B | 3.04B | 3.53B |
| Cash, Cash Equivalents and Short-Term Investments | 76.32M | 76.32M | 150.63M | 34.00M | 14.94M | 226.56M |
| Total Debt | 0.00 | 2.24B | 1.77B | 1.16B | 1.09B | 1.08B |
| Total Liabilities | -1.44B | 3.73B | 3.55B | 3.16B | 3.36B | 3.76B |
| Stockholders Equity | 1.44B | 1.44B | 592.72M | 279.41M | -61.54M | -234.20M |
Cash Flow | ||||||
| Free Cash Flow | -247.74M | -568.35M | -229.26M | -134.45M | 71.69M | 308.65M |
| Operating Cash Flow | -56.53M | 27.76M | 261.02M | 39.78M | 197.97M | 405.23M |
| Investing Cash Flow | -152.68M | -571.12M | -511.74M | -166.25M | -88.38M | 5.87M |
| Financing Cash Flow | 213.44M | 518.87M | 257.33M | 145.53M | -319.91M | -285.85M |
Wanbury Limited Technical Analysis
Negative
332.50
Price Trends
258.69
Negative
269.67
Negative
254.72
Negative
Market Momentum
-12.51
Positive
25.21
Positive
8.23
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:WANBURY, the sentiment is Negative. The current price of 332.5 is above the 20-day moving average (MA) of 231.17, above the 50-day MA of 258.69, and above the 200-day MA of 254.72, indicating a bearish trend. The MACD of -12.51 indicates Positive momentum. The RSI at 25.21 is Positive, neither overbought nor oversold. The STOCH value of 8.23 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:WANBURY.
Wanbury Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | ₹15.50B | 34.96 | ― | 1.68% | 3.87% | -25.38% | |
78 Outperform | ₹11.74B | 12.16 | ― | 0.31% | 10.20% | 11.70% | |
64 Neutral | ₹8.97B | 19.82 | ― | 1.71% | 9.70% | 21.04% | |
63 Neutral | ₹7.71B | 24.17 | ― | 0.40% | 14.04% | 2.57% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
50 Neutral | ₹7.17B | 168.26 | ― | 0.15% | 7.55% | -57.19% | |
49 Neutral | ₹7.59B | 11.54 | ― | 1.20% | 3.63% | 24.22% |
* General Sector Average
IN:WANBURY
Wanbury Limited
198.90
-51.15
-20.46%
IN:JAGSNPHARM
Jagsonpal Pharmaceuticals Ltd.
237.10
18.17
8.30%
IN:KILITCH
Kilitch Drugs (India) Limited
214.55
41.73
24.14%
IN:LINCOLN
Lincoln Pharmaceuticals Ltd
585.25
53.41
10.04%
IN:ZIMLAB
Zim Laboratories Ltd.
137.95
65.95
91.60%
IN:ANUHPHR
Anuh Pharma Limited
87.71
6.14
7.52%
Wanbury Limited Corporate Events
Wanbury Gains USFDA DMF Clearance for Metformin API, Bolstering Global Expansion
Jul 30, 2026
Wanbury Limited announced that it has received a “No DMF deficiency” communication from the U.S. Food and Drug Administration for multiple ANDAs that use its Metformin HCl API in different formulations, indicating full compliance of it...
Wanbury says USFDA audit at Tanuku plant poses no material business impact
Jul 22, 2026
Wanbury Limited has reported that the U.S. Food and Drug Administration has completed a routine current Good Manufacturing Practices inspection at its Tanuku manufacturing facility in Andhra Pradesh. The inspection, conducted from July 13 to July ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.